The Latest Cardiac and Vascular News
Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood PRINCETON, N.J., Feb. 23, 2026 /PRNewswire/ — Bracco, a global leader in diagnostic imaging, today announced that the…
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The expan
Live demonstrations of the Nanox.ARC will feature at the ECR booth #425 in Hall X4Oral presentation by Dr. Nogah Shabshin to present data on potential role of digital tomosynthesis in lung cancer screeningOral presentation by Dr. Orit Wimpfheimer to explore how Nanox AI transforms routine CT scans into tools for early detection of cardiovascular disease, osteoporosis and fatty liver diseasePoster presentations to highlight new clinical data from ADOPT study featuring AI bone solution PETACH TIKVA, Israel, Feb. 17, 2026 – NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI solutions in development at the European Congress of Radiology (ECR), taking place March 4-8, 2026 in Vienna, Austria. The Nanox.ARC is a CE-marked and FDA-cleared, multi-source digital tomosynthesis system that makes 3D imaging possible in more places, at a lower cost and significantly reduced radiation dose than traditional CT. Nanox.ARC’s smaller footprint and simplified installation requirements make it well-suited to a range of European healthcare settings, from major medical centers to community clinics. Software upgrades and new capabilities can be added remotely following regulatory clearances. Live demonstrations of the Nanox.ARC will be featured at booth #425 (Hall X4) every 30 minutes. The Company will present new clinical data on the potential role of digital tomosynthesis in lung cancer screening and demonstrate the Nanox.ARC’s TAP2D cloud-enabled image enhancement, recently FDA-cleared. Nanox will also showcase Nanox.AI’s FDA-cleared solutions that analyze routine CT scans for indicators of chronic diseases – AI Cardiac solution (HealthCCSng) and AI Bone solution (HealthOST), both of which have also received CE Mark certification, as well as AI Liver solution (HealthFLD). Additionally, Nanox will present two new AI solutions under development for aortic valve calcification and body composition measurement. Poster presentations will feature new data from the ADOPT study conducted at National Health Service hospitals in the United Kingdom, demonstrating the impact of AI-enabled vertebral fracture identification on clinical workflows and treatment recommendations. “Presenting the Nanox.ARC live in Europe for the first time, a year after receiving CE Mark certification, represents a significant milestone in our European market expansion,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “European healthcare systems need advanced imaging solutions that can operate beyond major medical centers, and that is exactly what the Nanox.ARC was designed to do. At ECR 2026, we will highlight new AI capabilities and clinical evidence demonstrating the performance of the capabilities of the Nanox.ARC in lung cancer screening, as shown in clinical studies. We remain focused on making high-quality imaging more affordable, more accessible and available at scale with our end-to-end imaging solutions.” Nanox representatives will be available throughout ECR 2026 for product demonstrations and discussions of clinical data and collaboration opportunities. Schedule a meeting at booth #425 More details about Nanox’s ECR 2026 presentations and events are as follows: Oral Presentation: The potential role of Digital Tomosynthesis in improving the efficiency of Lung Cancer Screening at reduced radiation doses, costs and radiologists burden Presenter: Nogah Shabshin, MD (Medical Director, ARC Division of Nanox)Location: Research Stage 6Session Title: RPS 304 – Hot Topic: AI-driven lung cancer screeningSession Day/Time: Wednesday, March 4, 2026 at 11:30 am – 12:30 pm CET Oral Presentation: Activating Latent Data to Promote Early Detection: The Role of AI in CT Imaging Presenter: Orit Wimpfheimer, MD (Chief Medical Officer of Nanox)Location: AI Theatre (Level -2, Room D1)Session Title: AI-IND 2 – AI Lightning Talks 2Session Day/Time: Wednesday, March 4, 2026, at 11:00 am – 12:00 pm CET Poster Presentation: Tomosynthesis Augmented Projection (TAP2D) vs Conventional Chest Radiography as a Supplement to Digital Tomosynthesis: A Pilot Study Presenter: Nogah Shabshin, MD (Medical Director, ARC Division of Nanox)Location: EPOS Area, Level -2 Poster Presentation: Tomosynthesis Augmented Projection (TAP2D) vs Conventional [Musculoskeletal] Radiography as a Supplement to Digital Tomosynthesis: A Pilot Study Presenter: Nogah Shabshin, MD (Medical Director, ARC Division of Nanox)Location: EPOS Area, Level -2 Poster Presentation: Comparison of radiology augmented vs asynchronous implementation of AI enabled Vertebral Fracture reporting Presenter: Orit Wimpfheimer, MD (Chief Medical Officer of Nanox)Location: EPOS Area, Level -2 Poster Presentation: Impact of AI-enabled vertebral fracture (VF) identification on Fracture Liaison Service (FLS) Key Performance Indicators (KPIS) and treatment recommendations Presenter: Orit Wimpfheimer, MD (Chief Medical Officer of Nanox)Location: EPOS Area, Level -2 Cocktail Event Location: Altia Skybar (57 Lounge, 58th Floor)Day/Time: Thursday, March 5, 2026, at 5:30-7:30 pm CETPresentation to be given by Emilio Quaia, MD (Professor of Radiology, University of Padova)Registration Link About Nanox Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes. The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery. By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision Forward-Looking Statements This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations. Contacts Media Contact:Jessica Hodgson ICR HealthcareNanoxPR@icrinc.com Investor Contact:Mike CavanaughICR Healthcaremike.cavanaugh@icrhealthcare.com
– New Academic Data Supports Clinical and Commercial Value of Hybrid Imaging Platform-TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (“Conavi” or the “Company”), a leader in hybrid intravascular imaging technologies, today highlighted the publication of new peer-reviewed research titled “Deep learning-based plaque characterization in hybrid IVUS-OCT images is superior to single-modality deep learning analysis and human experts: head-to-head comparison against histology,” published in Cardiovascular Research by the European Society of Cardiology. The study analyzed IVUS-OCT images and matched histological sections from 10 cadaveric human hearts, demonstrating that a histology-trained hybrid IVUS-OCT deep-learning classifier outperformed single-modality IVUS, single-modality OCT, and expert readers in plaque characterization, supporting the clinical and commercial value of a comprehensive hybrid imaging for enhancing treatment planning. The publication includes contributions from Dr. Brian Courtney, a pioneer in hybrid IVUS-OCT imaging and co-inventor of the foundational hybrid imaging technology that underpins Conavi’s platform. Co-authors included imaging experts in Canada, Europe and the USA, as well as artificial intelligence researchers at Queen Mary University of London. “Peer-reviewed academic research continues to reinforce the clinical value proposition behind Conavi’s technology platform,” said Tom Looby, Chief Executive Officer of Conavi Medical. “As the field moves toward more precise, image-guided coronary interventions, research highlighting the complementary strengths of IVUS and OCT underscores the importance of comprehensive hybrid systems.” Conavi is advancing the development and commercialization of its next-generation hybrid IVUS-OCT imaging solutions and has submitted its next-generation Novasight imaging system to the U.S. Food and Drug Administration (FDA) for regulatory clearance, while continuing preparations to support commercialization and clinical adoption. For additional details, the publication can be accessed at:https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvaf281/8443065 Stock Option Grant The Company also announced that it has granted stock options to Mark Quick, Chief Financial Officer on February 10, 2026. As part of its long‑term incentive program, the Company granted options to purchase a total of 1,000,000 common shares at an exercise price equal to the five-day volume‑weighted average trading price (“VWAP”) of the shares on the date of grant, being $0.41 per share. The options vest in accordance with the Company’s stock option plan and expire ten years from the date of grant. The grant of these options remains subject to all necessary regulatory approvals. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has 510(k) regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit http://www.conavi.com. Notice on forward-looking statements:This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to Conavi’s plans for the commercialization of its Novasight Hybrid™ System and the regulatory approval thereof, and the value proposition behind Conavi’s technology platform. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the amended and restated short form prospectus dated January 7, 2026 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company’s profile at www.sedarplus.ca). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. CONTACT:Chief Financial Officer: Mark Quick, 416-483-0100 Investors: Christina Cameron, 416-483-0100 ext.121, IR@conavi.com
Seasoned finance and operations leader will focus on expanding cardiac CT access for clinics and cardiology practices nationwide. Caesarea, Israel – Feb. 3, 2025 – Arineta, a leader in advancing cardiovascular imaging solutions, today announced the appointment of Einav Ehre by its board of directors as interim Chief Executive Officer, effective immediately. […]
eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unnecessary follow-up procedures, and has the potential to help save hundreds of thousands of lives in the US alone eyonis® LCS is the only device capable of both detecting […]
ReadyFix will first be deployed with GE HealthCare’s MAC VU360* resting electrocardiogram (ECG) workstations to help optimize cardiac care delivery by reducing device disruptions. Through real-time** data and remote device diagnostic capabilities, ReadyFix can help healthcare systems proactively maintain and optimize MAC VU360 devices anywhere in the hospital — supporting […]
Microbot Medical® to Leverage Current Users
Experience of LIBERTY® at Key Oncology
Conference to Support Commercial Adoption.
Interventional oncology procedure on Philips Azurion
Interventional oncology procedure on Philips Azurion
Members of the PreciseOnco consortium team
Members of the PreciseOnco consortium team
PreciseOnco research consortium logo
PreciseOnco research consortium logo
February 3, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the Philips-coordinated research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and enhance the precision of minimally invasive cancer treatmentsFive-year research program with total budget of EUR 23.9 million includes five clinical studies to validate the technical solutions, with the aim of setting a new benchmark for precision, safety, and efficiency in minimally invasive cancer care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the PreciseOnco consortium, coordinated by Philips, has been awarded funding from the EU’s Innovative Health Initiative (IHI) to advance precision cancer treatment through the integration of advanced medical imaging, robotic assistance, and minimally invasive therapies. The EUR 14.9 million public funding will be complemented by EUR 9 million in in-kind contributions and additional resources from industry partners, supporting a five-year research and innovation program that also includes five clinical studies. “Smart imaging and robotic precision are opening new possibilities for minimally invasive cancer treatment,” said Bert van Meurs, Chief Business Leader for Image Guided Therapy at Royal Philips. “By combining spectral imaging, AI-powered software and robotic guidance, we’re developing new solutions to help physicians treat cancer with greater precision, confidence and speed. This leads to better outcomes for patients and a more efficient use of hospital resources. The PreciseOnco partnership brings together technology, clinical expertise and patient perspectives to help improve the way cancer care is delivered.” Innovation through public-private partnershipThe PreciseOnco public-private partnership unites experts from industry, research organizations, medical societies and leading European hospitals: Industry partners: Philips, Quantum Surgical, and IGEAResearch organization: European Institute for Biomedical Imaging Research (EIBIR)Medical society: Cardiovascular and Interventional Radiological Society of Europe (CIRSE)Academic partners: University Hospital Cologne (Uniklinik Koeln) in Germany, University Medical Center Utrecht (UMCU) and Leiden University Medical Center (LUMC) in the Netherlands, and two major university hospital networks in France: Assistance Publique–Hôpitaux de Paris (APHP; Hôpital Henri-Mondor) and Hospices Civils de Lyon (HCL) By uniting Europe’s leading clinical expertise and industry innovation, PreciseOnco aims to set a new benchmark for precision, safety, and efficiency in minimally invasive cancer care. The rising cancer burden and precision treatment needsCancer remains a leading health challenge, with approximately 2.7 million new diagnoses in Europe each year [1] with projections suggesting over 35 million new cancer cases globally by 2050, representing a 77% increase from 2022 [2]. In response to this growing challenge, interventional oncology has emerged as a rapidly evolving discipline that integrates medical imaging, oncology, and minimally invasive treatment approaches [3]. Such treatments – including targeted ablation, radioembolization, and electrochemotherapy – offer advantages over traditional surgery, such as shorter recovery times and fewer side effects; however, their effectiveness strongly depends on the performance of medical imaging and the precision with which physicians can guide instruments to tumors. Bringing advanced technology into the interventional roomThe PreciseOnco consortium aims to develop a suite of integrated technologies designed to take the next leap in precision cancer care. Central to the research and innovation program is spectral imaging, an advanced form of CT and cone-beam CT that captures significantly richer information about tissue composition than conventional imaging, enabling more confident differentiation between tumors, vasculature, and healthy tissue. By analyzing X-rays at different energy levels, spectral imaging enables physicians with greater clarity to see exactly what tissues they are treating. To complement this advanced imaging technology, PreciseOnco will integrate robotic guidance systems that use real-time imaging data to guide interventional instruments (one or multiple needles) with sub-millimeter precision. The consortium will also look to advance electrochemotherapy, a minimally invasive technique that combines locally administered electrical pulses with chemotherapy to selectively treat cancer tissue, with the aim of maximizing tumor control while preserving surrounding healthy tissue. Crucially, all these technologies will be powered by AI algorithms designed to enhance image quality, reduce radiation dose, streamline advanced visualization software and provide real-time intra-procedural feedback on treatment success. This would allow physicians to confirm that tumors have been fully treated before the patient leaves the operating room. Clinical studiesThe project is structured into multiple work packages covering spectral imaging technology development, AI based image processing, robotic guidance integration, multi-center clinical validation, and health economic assessment. PreciseOnco will conduct five clinical studies spanning multiple cancer types and interventional workflows, ensuring robust validation in real world clinical settings: VISTA (Virtual Spectral Imaging for Superior Thermal Ablation Guidance): Evaluating spectral imaging to improve liver, kidney ablation procedures and liver radioembolization.SPOT ON (Spectral angiography-computed tomography to Optimize percutaneous Tumor ablation): Assessing spectral CT for better tumor targeting and treatment planning.HORA EST HCC 2: Combining thermal ablation with transarterial chemoembolization (TACE) in a single session for improved hepatocellular carcinoma treatment.SPECTRA-L (Spectral Performance Evaluation of a CT-Equipped Therapeutic Radiology Angio Suite in Liver): Testing spectral imaging for transarterial chemoembolization (TACE) procedures.LASER (Locoregional therApies Spectral Evaluation of Responses): Developing imaging biomarkers to predict treatment success across multiple cancer types and interventional techniques. Together, these studies will generate evidence to support the adoption of spectral imaging and robotic guidance across European cancer centers, extending access to advanced minimally invasive treatments to a larger patient population. Philips and innovation public-private partnershipsPublic-private partnerships play a vital role in advancing healthcare innovation. With over 40 years of experience in shaping and leading such partnerships, Philips sees them as a powerful complement to its global R&D programs, helping build sustainable ecosystems that foster innovation. Philips’ broad imaging, image-guided therapy, and healthcare informatics portfolio helps clinicians visualize, assess, guide treatment, and confirm outcomes – supporting more precise and personalized care. With innovations like Verida detector-based spectral CT fully powered by AI and Azurion image-guided therapy system, Philips continues to push the boundaries of imaging technology, advanced visualization and minimally invasive therapy worldwide. The PreciseOnco project website will be available soon at www.preciseonco.eu. The CORDIS project page for PreciseOnco can be accessed here. The IHI factsheet for PreciseOnco can be found here. References[1] European Cancer Information System (ECIS) – jrc_CancerEstimates2022_factsheet.pdf.[2] World Health Organization (WHO) – Global cancer burden growing, amidst mounting need for services.[3] Global Interventional Oncology Market report – Interventional Oncology Market Size and Growth Analysis Report. This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No. 101252582. The JU receives support from the European Union’s Horizon Europe research and innovation program and life science industries represented by COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. PreciseOnco is funded by the European Union, private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them. For further information, please contact: Joost MalthaPhilips Global External RelationsTel.: +31 610 558 116E-mail: joost.maltha@philips.com Steve KlinkPhilips Medical and Scientific CommunicationsTel.: +31 610 888 824E-mail: steve.klink@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
Interventional oncology procedure on Philips Azurion
Members of the PreciseOnco consortium team
PreciseOnco research consortium logo
First worldwide Allia Moveo installation at Hôpital Marie-Lannelongue in France highlights progress in redefining interventional care delivery Allia Moveo combines mobility, versatility and AI-powered tools to help clinicians navigate complex minimally invasive procedures with efficiency and accuracy CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. […]
